Alveolar Ridge Splitting With Simvastatin/PRF Composite and Simultaneous Implant Placement (ARS-SIMV)
Alveolar Ridge Splitting Augmented With Simvastatin/Platelet-Rich Fibrin Composite With Simultaneous Implant Placement in Horizontal Ridge Augmentation: A Randomized Controlled Clinical Trial
Visão geral do estudo
Status
Condições
Descrição detalhada
Horizontal alveolar ridge deficiency frequently complicates implant placement following tooth loss. Alveolar ridge splitting is a well-established technique for horizontal ridge augmentation that allows simultaneous implant placement when sufficient vertical bone height is available. However, the predictability of bone regeneration may be influenced by the grafting material used.
Platelet-rich fibrin (PRF) is an autologous biomaterial rich in platelets, leukocytes, and growth factors that may enhance angiogenesis, soft tissue healing, and bone regeneration. Simvastatin has also demonstrated osteogenic and angiogenic properties through stimulation of bone morphogenetic protein-2 (BMP-2) expression and inhibition of osteoclastic activity. Combining simvastatin with PRF may further improve regenerative outcomes.
This single-center, randomized controlled clinical trial included 21 participants with horizontal alveolar ridge deficiency requiring implant-supported rehabilitation. Participants were randomly allocated into three equal groups (n = 7 per group). Group I underwent alveolar ridge splitting with simultaneous implant placement and augmentation using a xenogeneic bone graft. Group II received a xenogeneic bone graft blended with PRF. Group III received a xenogeneic bone graft blended with a simvastatin/PRF composite.
Clinical and radiographic evaluations were performed to assess horizontal bone gain, vertical bone gain, bone density using cone-beam computed tomography (CBCT), and keratinized tissue width. The study aimed to determine whether the addition of PRF alone or in combination with simvastatin could improve regenerative outcomes compared with conventional xenogeneic bone grafting.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Giza Governorate
-
Cairo, Giza Governorate, Egito
- Faculty of Oral and Dental Surgery, Misr University for Science and Technology
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
Horizontal alveolar ridge width of 3-5 mm. Vertical alveolar bone height of ≥11 mm. Edentulous site located in the mandibular anterior region. Absence of buccal bone undercuts. Male or female participants aged 18-50 years. Good general health and medically fit to undergo oral surgical procedures. Absence of periapical pathology at the intended implant site. Adequate crown height space to achieve a favorable crown-to-implant ratio. Willingness and ability to attend all scheduled follow-up visits. Provision of written informed consent.
Exclusion Criteria:
Uncontrolled systemic diseases (e.g., uncontrolled diabetes mellitus), active infection, bleeding disorders, or current anticoagulant therapy.
Severe systemic diseases (e.g., uncontrolled hypertension or severe cardiovascular disease).
Severe alveolar bone deficiencies not suitable for ridge splitting. Pregnancy or breastfeeding. Inability to comply with postoperative instructions or follow-up visits. Known allergy or hypersensitivity to simvastatin or study materials. Individuals from vulnerable populations unable to provide valid informed consent.
Bruxism or other parafunctional oral habits.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: control group
Participants underwent alveolar ridge splitting with simultaneous implant placement and augmentation using a xenogeneic bone graft.
|
Surgical expansion of the horizontally deficient alveolar ridge followed by immediate dental implant placement.
Xenogeneic bone graft used to augment the expanded alveolar ridge around the implant.
|
|
Experimental: PRF Group
Participants underwent alveolar ridge splitting with simultaneous implant placement and augmentation using a xenogeneic bone graft blended with platelet-rich fibrin (PRF).
|
Surgical expansion of the horizontally deficient alveolar ridge followed by immediate dental implant placement.
Xenogeneic bone graft used to augment the expanded alveolar ridge around the implant.
Autologous platelet-rich fibrin prepared from the participant's blood and blended with the xenogeneic bone graft.
|
|
Experimental: Simvastatin/PRF Group
Participants underwent alveolar ridge splitting with simultaneous implant placement and augmentation using a xenogeneic bone graft blended with a simvastatin/platelet-rich fibrin (PRF) composite.
|
Surgical expansion of the horizontally deficient alveolar ridge followed by immediate dental implant placement.
Xenogeneic bone graft used to augment the expanded alveolar ridge around the implant.
Autologous platelet-rich fibrin prepared from the participant's blood and blended with the xenogeneic bone graft.
Locally applied simvastatin incorporated into the PRF/xenogeneic bone graft composite to enhance bone regeneration.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Horizontal Bone Gain
Prazo: 6 months after surgery
|
Horizontal bone gain was assessed by measuring the change in alveolar ridge width using cone-beam computed tomography (CBCT).
Measurements were obtained by superimposition of preoperative and 6-month postoperative CBCT scans at standardized reference levels.
|
6 months after surgery
|
|
Vertical Bone Gain
Prazo: 6 months after surgery
|
Vertical bone gain was assessed by comparing preoperative and 6-month postoperative CBCT scans using standardized reference points.
|
6 months after surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Bone Density
Prazo: 6 months after surgery
|
Bone density of the augmented site was evaluated using CBCT gray scale values.
|
6 months after surgery
|
|
Keratinized Tissue Width
Prazo: Baseline and 6 months after surgery
|
Keratinized tissue width was measured clinically using a calibrated periodontal probe.
|
Baseline and 6 months after surgery
|
|
Implant Stability
Prazo: Baseline (immediately after implant placement) and 6 months after surgery.
|
Implant stability was assessed using the Implant Stability Test (IST) device.
Measurements were recorded as IST values immediately after implant placement and at the 6-month follow-up.
|
Baseline (immediately after implant placement) and 6 months after surgery.
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- MUST-IRB-2024-0062
- 2024/0062 (Outro identificador: Misr University for Science and Technology Institutional Review Board (MUST-IRB))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .